Immunohistochemical Investigation of Mutant BRAF V600E in Common Pigmented Skin Neoplasms, Study on a Sample of Iranian Patients

Ghasemi, M; L, Vahedi Larijani; Emadian, Omid; Yazdani, Jamshid; Sajadianfar, A; Abediankenari, Saeid

doi:10.30699/ijp.14.1.8

Cited by 3 publications

(2 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a recent study, the prevalence of BRAF V600E mutation was evaluated in Iranian patients with pigmented cutaneous neoplasms. They revealed a high intensity of immunostaining for BRAF V600E in 60% of the cases in the malignant melanoma group, while not in other skin neoplasms, such as benign nevus (21). However, the relationship between BRAF V600E mutation and the transformation of a nevus to malignant melanoma remains obscure in the Iranian population.…”

Section: Discussionmentioning

confidence: 99%

Prevalence and Main Determinants of BRAF V600E Mutation in Dysplastic and Congenital Nevi

et al. 2021

View full text Add to dashboard Cite

Background & Objective: Predicting the transformation of dysplastic or congenital nevi into malignant lesions results in a significant increase in the survival of patients. Some specific gene mutations have been reported to be very helpful in this regard. Therefore, this study aimed to evaluate the prevalence of BRAF V600E mutation in dysplastic and congenital nevi. Methods: This cross-sectional study was conducted on patients with congenital (n=30) or dysplastic (n=30) nevi. For genomic analysis, the BRAF gene mutation (V600E) was evaluated using the real-time polymerase chain reaction. Results: The prevalence of BRAF gene (V600E) mutation was found as 1 case (3.3%) in congenital and 8 cases (26.7%) in dysplastic nevi indicating the higher prevalence of this mutation in patients with dysplastic nevi ( P =0.026). Moreover, in the dysplastic nevi group, the presence of BRAF gene mutation (V600E) showed a significant relationship with the severity of dysplasia as the mutation rate was 25% in mild cases, in comparison with 54.5% in moderate dysplasia cases ( P =0.009). Conclusion: According to the results, 3.3% of the patients with congenital nevi and 26.7% of the subjects with dysplastic nevi were positive for BRAF V600E mutation. Furthermore, the severity of dysplasia could have a positive relationship with the presence of the mutation.

show abstract

Section: Discussionmentioning

confidence: 99%

Prevalence and Main Determinants of BRAF V600E Mutation in Dysplastic and Congenital Nevi

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The prevalence varies by race: 1.9/100,000 in Hispanics 9.2/ 100,000 in whites, and 0.7% to 1.2/100,000 in blacks and Asian 1 . In spite of significant advancements in medicine, melanoma remains a huge burden on the healthcare system in developing countries due to the substantial annual costs incurred for its management 2 .…”

Section: Introductionmentioning

confidence: 99%

Immunohistochemical Expression of Brafv600e in Melanoma Cases

Umer

Akhtar

Jamal

et al. 2021

PAFMJ

View full text Add to dashboard Cite

Objective: To evaluate the diagnostic value of Immunohistochemistry (IHC) for finding BRAFV600E mutation in melanoma patients. Study Design: Cross-sectional study. Place and Duration of Study: Department of Histopathology, Armed Forces Institute of Pathology, Rawalpindi Pakistan, Jan 2018 to Apr 2019. Methodology: Hundred histologically confirmed cases of melanoma aged between 18-80 years were included over a period of one year. To create the tissue microarray and to conduct immunohistochemistry with VE1 antibody melanoma lesion samples were selected. Results: Ninety-four cases out of 100, were melanoma positive for BRAFV600E detected on immunohistochemistry (IHC) using a monoclonal antibody. The skin was the primary site in seventy-nine (79%) patients, unknown (metastatic) in nineteen and uveal was only in two cases. The diagnostic significance of immunohistochemistry (IHC) for detecting the BRAFV600E mutation in melanoma patients was independent of age, site and stage at diagnosis (p-value <0.05). Conclusion: Testing of BRAV600E mutation by immunohistochemistry is a rapid, reliable and cost-effective tool in melanoma patients which may further help clinicians in initiating targeted therapy for these patients.

show abstract

The Relationship Between Fibroblastic Growth Factor Receptor-1 (FGFR1) Gene Amplification in Triple Negative Breast Carcinomas and Clinicopathological Prognostic Factors

et al. 2019

View full text Add to dashboard Cite

Background & Objective: In Triple-Negative Breast Cancers (TNBCs), estrogen receptor (ER), progesterone receptor (PR) and HER2/neu genes are not expressed. Fibroblastic Growth Factor Receptor-1 (FGFR1) gene product is a protein that acts as a receptor of thyrosin kinase. It plays a role in the proliferation, differentiation, and migration of malignant cells. The objective was to evaluate the possible relation between FGFR1 over-expression and amplification in TNBCs and other clinicopathological variables. Methods: In this cross sectional study, purposive sampling was used to collect eighty-four TNBC specimens from mastectomy specimens collected between 2013 and 2017. Tissue microarrays were evaluated for FGFR1 over-expression and amplification respectively by immunohistochemistry (IHC) staining and real time Polymerase Chain Reaction (PCR). The needed clinical and paraclinical information were obtained from patients’ files. To analyze the correlation among prognostic factors, we used a wide range of different statistic methods, namely Chi-square test, independent t-test, Fisher's exact test, and ANOVA. Results: FGFR1 over-expression was found in 15 of the 84 samples (17.9%). FGFR1 gene amplification was observed in 33.3% (28 of 84) of the samples. We found no association between FGFR1 and clinicopathological parameters, including tumor grade, stage, and patient survival (P>0.005). Conclusion: FGFR1 over-expression and amplification may not be related to clinicopathological parameters, namely age, stage, and grade of the cancer not to mention TNBC survival. Using FGFR1 as a prognostic factor in TNBCs requires further study.

show abstract

Immunohistochemical Investigation of Mutant BRAF V600E in Common Pigmented Skin Neoplasms, Study on a Sample of Iranian Patients

Cited by 3 publications

References 22 publications

Prevalence and Main Determinants of BRAF V600E Mutation in Dysplastic and Congenital Nevi

Prevalence and Main Determinants of BRAF V600E Mutation in Dysplastic and Congenital Nevi

Immunohistochemical Expression of Brafv600e in Melanoma Cases

The Relationship Between Fibroblastic Growth Factor Receptor-1 (FGFR1) Gene Amplification in Triple Negative Breast Carcinomas and Clinicopathological Prognostic Factors

Contact Info

Product

Resources

About